Form 4: BioCryst Director Sells Shares Under Pre-Arranged Plan

Machelle Sanders, a director at BioCryst Pharmaceuticals, sold 9,600 shares of common stock for $7.14 per share under a Rule 10b5-1 trading plan.

Summary

• Machelle Sanders, a Director of BioCryst Pharmaceuticals Inc. (BCRX), sold 9,600 shares of common stock.
• The transaction occurred on November 13, 2025, at a price of $7.14 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Ms. Sanders on August 14, 2025.
• Following this transaction, Ms. Sanders beneficially owns 30,642 shares of BioCryst common stock.
• The sale was automatic and does not represent a discretionary transaction by the reporting person.

Sentiment

Score: 5

Explanation: The transaction is a pre-scheduled sale under a Rule 10b5-1 plan, which typically indicates a non-discretionary event and is generally viewed as neutral in terms of market sentiment.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This insider transaction report reflects a routine, pre-scheduled sale by a director and does not provide broader insights into industry trends or competitive landscape.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-scheduled under a 10b5-1 plan, indicating it was not based on new material non-public information.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Machelle Sanders, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Director, Common Stock